![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
Tag: Coronavirus information (COVID-19)
Drug Research
Roches Actemra/RoActemra receives U.S. FDA EUA for the treatment of COVID-19 in hospitalised adults and children
Roche announced that the U.S. FDA has issued an EUA for intravenous Actemra/RoActemra® (tocilizumab) for the treatment of COVID-19 in hospitalised adults and paediatric...
Clinical Trials
Tiziana and FHI Clinical work on Phase II intranasal Covid-19 drug trial
Tiziana Life Sciences plc, a biotechnology company focused on innovative therapeutics for oncology, neurology, inflammation and infectious diseases, announces that it has signed an...
Press Releases
AstraZeneca COVID-19 vaccine Vaxzevria authorised for emergency use in Japan
AstraZeneca’s COVID-19 vaccine, Vaxzevria (ChAdOx1-S ), formerly AZD1222, has been granted a special approval for emergency use in Japan for active immunisation of individuals...
Clinical Trials
Moderna Reports Positive COVID-19 Vaccine Results in Adolescents
Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that the Phase 2/3 study of its COVID-19 vaccine (mRNA-1273) in...
News
CanSino Biologics Gets OGYEI GMP Certificate for COVID Vax
CanSino Biologics Recombinant Novel Coronavirus Vaccine, (Adenovirus Type 5 Vector, trade name Convidecia), has been granted a Good Manufacturing Practice certificate by the Hungarian...
News
ANVISA Sorrento Phase 2 Pivotal Clinical Trial of COVI-MSC in Hospitalized COVID-19 Patients With Acute Respiratory Distress Syndrome
Sorrento Therapeutics, Inc. announced receipt of clearance from the Brazilian regulatory agency (ANVISA) to proceed with a Phase 2 Pivotal clinical trial of COVI-MSC™,...
Packaging & Labelling
Moderna and Samsung Biologics Announce Agreement for Fill-Finish Manufacturing of Modernas COVID-19 Vaccine
Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Samsung Biologics, a leading global CDMO providing a fully integrated end-to-end contract...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read